AAAya M. AbdelMagid

Aya M. AbdelMagid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aya M. AbdelMagid has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of Incentive Spirometer on Arterial Blood Gases in Liver Transplant Recipients

    by Amal Ahmed Mohamed, Aya M. AbdelMagid, Ahmed M. Kamel, Mostafa Mohamed Ibrahim Mater, Gehan H. AboEl-Magd, Tarek Abdelkader Sallam, Ahmad Ahmeda, Mark Monir Seddik, Rania S. Abdel Aziz, Nabila Abdelnasser Elgazzar, et al.

  • Transition to generic dolutegravir: immunologic, virologic, and metabolic outcomes in a resource-limited setting

    by Aya M. AbdelMagid, Ahmed Cordie, Rahma Mohamed, Heba Fahmy, Engy El Khateeb, Hend Hamed Tamim, Zeinab Ali Elsaadany, Zainab Wafik Masoud, Gamal Esmat, Ahmed M. Kamel

    Dolutegravir (DTG) is a preferred antiretroviral agent; however, real-world data on outcomes after switching from branded to generic DTG remain limited. This study aims to evaluate metabolic, immunological, and virological outcomes following the transition from branded to generic DTG in HIV treatment programs in resource-limited settings. A longitudinal analysis was conducted among 188 people living with HIV (PLWH) who transitioned to generic DTG-based regimens. Clinical, immunological, virological, and metabolic parameters were assessed at multiple time points before and after the transition (median pre-transition 21.7 months; post-transition 10 months). Analyses covered four periods: pre-transition, 0–3, 3–6, and > 6 months post-transition. Primary outcomes were CD4 count change and viral suppression (undetectable viral load). Metabolic effects included changes in weight, BMI, lipid profile, and HbA1c. Linear and generalized linear mixed-effects models were applied. Following transition to generic DTG, CD4 counts continued to rise at 8.9 cells/µL/month (p < 0.001), particularly those with baseline CD4 < 200, with 74.5% of PLWH showing immunological improvement. Viral suppression was higher from 57.4% pre-transition to 71.8% at > 6 months post-transition. LDL increased slightly (+ 0.55 mg/dL/month, p < 0.001), while triglycerides (− 0.73 mg/dL/month, p = 0.03) and HbA1c (− 0.01%/month, p = 0.01) decreased. BMI and weight showed no significant changes. Adverse drug reactions occurred in 12.2%, most commonly sleep disturbance (4.89%). Transitioning from branded to generic DTG was associated with sustained immunological and virological outcomes and stable metabolic parameters. These findings support generic DTG as a safe, effective, cost-saving option for routine HIV care in resource-limited settings. Graphical Abstract

  • Beyond Monotherapy: The Superior Efficacy of Combined GLP ‐1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta‐Analysis

    by Aya M. AbdelMagid, Ahmed M. Kamel, Samar F. Farid

    Diabetic kidney disease (DKD) is a leading cause of chronic and end‐stage renal diseases. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) confer renoprotection; however, emerging evidence suggests that combination therapy has synergistic benefits. This meta‐analysis evaluated dual versus monotherapy, focusing on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted. PubMed, Scopus, Embase, CINAHL, Medline, and Web of Science were searched until August 2025 for RCTs comparing GLP‐1RA plus SGLT2i versus monotherapy or placebo in adults with T2D. The primary outcome was the change in UACR, and the secondary outcome was eGFR. Pooled standardized mean differences (SMD) were estimated using random‐effects models, including subgroup and sensitivity analyses. Eight RCTs ( n = 1974; sample size, 41–4000; follow‐up, 16 weeks–3.4 years) were included. Combination therapy was well tolerated and significantly reduced UACR compared with monotherapy (SMD –0.25, 95% confidence interval (CI) –0.38, −0.13; I 2 = 0%). The benefits remained significant against SGLT2i alone (SMD, −0.28) but not for GLP‐1RA alone. For eGFR, dual therapy provided a modest benefit versus SGLT2i (SMD 0.12, 95% CI 0.00–0.23) but not for GLP‐1RA. The effects were consistent in patients with DKD and in larger trials. Early SGLT2is and GLP‐1RA combination therapy is safe and provides superior renoprotection compared to monotherapy in patients with type 2 diabetes, albuminuria, and high cardiorenal risk. Broader adoption of combination therapy could improve outcomes, although cost and access barriers remain an issue.

  • Open Access

    Bioequivalence evaluation of two cariprazine hard capsule formulations

    by Mamdouh R. Rezk, Kamal A. Badr, Ahmed Abd El Hamid Hosny, Aya M. Abdel Magid

    Cariprazine, a third-generation antipsychotic, is indicated for schizophrenia and bipolar I disorder. Affordable formulations are essential for improving access and adherence, particularly in resource-limited settings. We aimed to assess the bioequivalence, safety, and tolerability of a newly developed generic hard capsule Vocarzine (1.5 mg) compared to a branded reference product of cariprazine hard capsule (Reagila®) under fasting conditions in healthy adult participants. In a randomized, open-label, single-dose, two-period, two-sequence crossover design, 30 healthy male and female participants received a single oral dose of either the test or reference product, with 4-week washout period. Pharmacokinetics were evaluated using validated LC–MS/MS methods. Bioequivalence was concluded if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of peak plasma concentration (C max ) and area under the concentration–time curve from time zero to 72 h (AUC 0-72h ) fell within 80–125%. Twenty-nine participants completed the study. The GMR (90% CI) for C max was 91.92% (85.07–99.33%) and for AUC 0-72h was 92.85% (88.86–97.02%), both within the bioequivalence acceptance range (80–125%). Both formulations were well tolerated; mild nausea was the most common adverse event, and no serious adverse events were reported. The two hard capsule formulations were bioequivalent, in terms of rate and extent of absorption, with a comparable safety profile, supporting the use of vocarzine as a safe, effective, and potentially cost-saving alternative. Clinical trial number: The ClinicalTrials.gov registration number is NCT07121868, retrospectively registered on August 13, 2025.


  • Open Access

    Medication reconciliation in clinical practice: a survey of knowledge, attitude, and practices among Egyptian healthcare providers

    by Aya M. AbdelMagid, Nirmeen A. Sabry, Ahmed Abuelhana, Aaron Courtenay, Amani M. Ali

    Background: Patients are at significant risk of harm from unintended medication errors, which remain prevalent and often preventable in healthcare systems, especially in low- and middle-income countries. Medication reconciliation (MedRec) plays a critical role in minimizing these errors by ensuring an accurate and complete medication list throughout patient transitions in the healthcare system. Aim: This study aimed to assess the current status of the MedRec process in Egypt by exploring the knowledge, attitudes, and practices of physicians and pharmacists as key stakeholders in its implementation. Methods: This descriptive, cross-sectional study used a structured, validated, self-administered online questionnaire targeting Egyptian physicians and pharmacists. The questionnaire was distributed via snowball sampling through professional networks and social media. Branching logic was used to tailor questions based on respondents’ familiarity with MedRec and hospital-based practices. Descriptive statistics were used to summarize the responses, while Chi-square and Mann–Whitney U tests were used to assess group differences. Results: Among 272 respondents (182 pharmacists, 90 physicians), representing multiple Egyptian governorates and healthcare sectors (public, private, and military). Among them, 66.9% reported familiarity with MedRec, significantly higher among pharmacists (73.1% vs. 54.4%; p = 0.002). Most respondents (70.2%) rated MedRec as “very valuable” for patient safety, and both groups expressed strong responsibility for its core tasks. Among the 136 hospital-based respondents familiar with MedRec, 79.4% reported institutional implementation. Physicians were more likely than pharmacists to ask patients for their current medication lists (93.8% vs. 76.1%; p = 0.021). Sources of medication history included patient lists or physician documents (74.3%), family interviews (74.3%), medication boxes from home (59.56%), discharge orders (52.2%), and transfer orders from other facilities (33.8%). Conclusion: Continuous education and training programs are required to close knowledge gaps, strengthen MedRec practices, and promote a culture of patient safety in Egypt.

  • Open Access

    Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent

    by Mamdouh R. Rezk, Kamal A. Badr, Ahmed Abd El Hamid Hosny, Aya M. AbdelMagid

    Purpose: While imeglimin’s, oral antidiabetic agent, efficacy and safety are established in Japanese and Western populations, pharmacokinetic data from Middle Eastern and African cohorts remain limited. This study aimed to evaluate the bioequivalence of test and reference imeglimin formulations under fasting conditions in healthy Egyptian adults. Methods: In a randomized, open-label, two-period, two-sequence crossover trial, healthy male and female adults received a single 500 mg oral dose of either formulation under fasting conditions, separated by a one-week washout. Adverse events (AEs) were assessed via direct questioning, participants’ reporting, vital signs monitoring, and clinical laboratory evaluations. Plasma concentrations were measured up to 72 h post-dose, and pharmacokinetic parameters were derived using non-compartmental analysis. Bioequivalence was concluded if the geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for peak plasma concentration (C max ), area under the concentration–time curve to 72 h (AUC 0-72 ), and to infinity (AUC 0–inf ) were within 80–125%. Results: In 29 healthy participants, all pharmacokinetic endpoints met bioequivalence criteria. GMR (90% CI) for each pharmacokinetic endpoint were: C max 101.75% (94.42–109.64); AUC 0–72 100.66% (94.28–107.46); AUC 0–inf 100.13% (93.77–106.92). The intrasubject variability was low (14–17%). Both formulations were well tolerated, with only mild transient adverse events (headache, abdominal pain) and no serious events. Conclusion: The test formulation of imeglimin was bioequivalent to the reference, with a favorable safety profile. This first pharmacokinetic and bioequivalence study in a Middle Eastern/African population supports regulatory approval and enhances opportunities for affordable access to imeglimin in type 2 diabetes management. Clinical trial number. The ClinicalTrials.gov registration number is NCT07127094, retrospectively registered on August 15, 2025. Graphical


  • Open Access

    Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study

    by Aya M. AbdelMagid, Kamal A. Badr, Mamdouh R. Rezk

    Background and Objective Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have difficulty swallowing tablets. The unavailability of an affordable generic perampanel oral suspension formulation increased the need for a cheaper bioequivalent alternative to the marketed reference product. The study aimed to assess the bioequivalence of two formulations of perampanel oral suspension (0.5 mg/mL) administered under fasting conditions focusing on providing a cost-effective and accessible alternative to current formulations. Methods This was an open-label, two-period, two-sequence, crossover, bioequivalence study conducted under fasting conditions. Healthy subjects were randomized to receive single doses of perampanel oral suspension (12 mg), Lepsiramp and Fycompa® separated by a 6-week washout period. The maximum concentration and area under the concentration–time curve up to 72 h were the primary pharmacokinetic parameters used to assess bioequivalence. Results The geometric mean ratio of test to reference formulations and 90% confidence interval were 109.55 (99.49–120.64) for maximum concentration and 98.15 (90.68–106.23) for the area under the concentration–time curve up to 72 h, which were within the 80–125% bioequivalence range. The adverse events were mild headache and dizziness. Conclusions The two oral suspension formulations were bioequivalent, safe, and well tolerated. This provides a beneficial affordable alternative for patients requiring non-tablet oral formulations. Clinical Trial Registration The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025.


  • Open Access

    Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis

    by Amani M. Ali, Mohamed E. Abdelrahim, Aya M. AbdelMagid

    Background: Autoimmune hepatitis (AIH) is a chronic progressive inflammatory liver disease of immune-mediated origin, which causes long-term liver inflammation and damage. Traditionally, treatment includes azathioprine (AZA) combined with steroids, but recent studies have highlighted mycophenolate mofetil (MMF) as a potential alternative, particularly for patients who do not respond well to AZA. Aims: This study aimed to evaluate the efficacy and safety of MMF versus AZA combined with steroids as first-line treatment for the management of AIH patients. Methods: A comprehensive systematic review was conducted using the keywords: mycophenolate mofetil, Cellcept, and autoimmune hepatitis. Studies comparing MMF to AZA combined with steroids in treatment-naïve patients with AIH were included. Efficacy was assessed based on complete biochemical remission (CBR), non-response, and relapse rates. Safety was evaluated on the basis of the incidence of serious adverse effects that led to treatment discontinuation. Statistical analysis included calculation of odds ratios (OR) and 95% confidence intervals (CI). Results: Out of 344 search results, four studies met the inclusion criteria, encompassing a total of 512 patients. MMF combined with prednisolone significantly improved both short-term CBR rates (OR, 2.56; 95% CI, 1.18–5.55) and long-term CBR rates (OR, 5.51; 95% CI, 1.7–17.91) compared to AZA combined with prednisolone. Furthermore, MMF treatment was associated with a significantly lower occurrence of serious adverse events (OR, 0.15; 95% CI, 0.07–0.34). Conclusions: Compared to AZA-based regimens, MMF-based first-line therapy for AIH appears to be a more promising, effective, and safe treatment option, yielding higher CBR rates and fewer serious adverse events requiring treatment discontinuation.


  • Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia

    by Aya M. AbdelMagid, Maggie M. Abbassi, Fatma S. Ebeid, Manal H. El-Sayed, Samar F. Farid